VIVUS Inc. (VVUS)

3.95
NASDAQ : Health Technology
Prev Close 3.83
Day Low/High 3.83 / 3.96
52 Wk Low/High 2.15 / 5.78
Avg Volume 114.10K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 40.76M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Biotech Mailbag: Xoma Looks Promising

Xoma's promising study results on a diabetes drug makes it more likely it will find a partner.

Health Winners & Losers: Acadia

Shares of the biopharmaceutical company slid after it posted a widened quarterly loss and slashed staff.

Thursday's Winners & Losers: Kosan Biosciences

Thursday's Winners & Losers: Kosan Biosciences

Shares jump 228.5% on a report that Bristol-Myers Squibb will buy the company.

Health Winners & Losers: Kosan

Kosan BioSciences soars on buyout news.

Health Winners & Losers: Vivus

Health Winners & Losers: Vivus

Vivus climbs on interim data for a midstage study on obesity drug Qnexa.

Health Winners & Losers: Merck

Merck slips on news of a discontinued study.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Merck climbs on settlement news.

Biotech Notebook: Dendreon, Orexigen, Arena, Hythiam

Dendreon's still dizzying, and other stock news from the biotech world.

Feuerstein's Biotech-Stock Mailbag

A special weekday edition tackles Arena Pharma and Vivus.

Monday's Health Winners & Losers

Vivus climbs on a nod from the FDA.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Corcept Therapeutics climbs on positive study data.

Friday's Small-Cap Winners & Losers

Friday's Small-Cap Winners & Losers

Image Entertainment climbs on news it will be acquired.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Replidyne is plunging.

Vivus Gains on Study

Vivus Gains on Study

Qnexa patients lose more weight in the Phase 2 trial.

Today's Health Winners and Losers

Medco and McKesson advance after posting strong results.

Health Stocks in Motion

Health Stocks in Motion

Vivus is climbing after positive results from a study.

Health Stocks in Motion

Health Stocks in Motion

Hi-Tech Pharmacal rises on solid third-quarter earnings.

FDA Looks at P&G's Sex-Drive Drug

FDA Looks at P&G's Sex-Drive Drug

An agency staff report raises questions about the company's female hormone drug Intrinsa.

P&G Gambles on Intrinsa

P&G Gambles on Intrinsa

Can it do for women what Pfizer's Viagra did for men?

Health Stocks in Motion

Health Stocks in Motion

Vivus is up on phase II trial success.

Early Isn't Always Better

Being early into positions was good during the bull market but is dangerous in the current environment.

TheStreet Quant Rating: D (Sell)